Savara (SVRA)

NasdaqMarket Closed

Savara Inc. is a clinical-stage biotechnology company developing therapies for rare respiratory diseases, with a particular focus on conditions that have limited approved treatment options. The company’s work is centred on specialty pharmaceuticals for the respiratory system, where disease biology, delivery method, and patient population require targeted development strategies rather than broad primary-care commercial models.

Savara’s lead programme is molgramostim, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF. The candidate is being studied for autoimmune pulmonary alveolar proteinosis, often abbreviated as aPAP, a rare lung disease in which impaired surfactant clearance leads to the build-up of material in the alveoli and can reduce oxygen transfer. By delivering GM-CSF directly to the lungs, molgramostim is designed to address the underlying immune signalling deficiency associated with the disease.

The company’s investment case is closely tied to the clinical and regulatory progress of molgramostim, which is in Phase 3 development. As with many rare-disease biotechnology companies, Savara’s value depends on successful trial outcomes, interactions with regulators, manufacturing readiness, intellectual property protection, and the ability to serve a small but medically significant patient group. It does not operate like a diversified pharmaceutical manufacturer; instead, it concentrates resources on a narrow therapeutic area where specialist knowledge and focused clinical execution are central.

Savara is headquartered in the United States and trades on Nasdaq under the ticker SVRA. Investors typically follow the company for developments in rare pulmonary medicine, late-stage clinical data, regulatory milestones, and the potential commercial opportunity for an inhaled therapy in aPAP.

5.37USD
+0.00(0.00%)

Last updated

Market Cap
$1,103,320,281
P/E
P/FCF
P/S
Enterprise Value
$1,091,629,281
Sector
Materials
Industry
Pharmaceutical Preparations
Address
6836 BEE CAVE ROAD, AUSTIN, TX, 78746
globenewswire.com

SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

24 Jan 2026, 16:38 PM
globenewswire.com

SVRA DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

06 Nov 2025, 01:57 AM
globenewswire.com

SVRA DEADLINE: ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

02 Nov 2025, 23:47 PM
globenewswire.com

SVRA FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

30 Oct 2025, 23:32 PM
globenewswire.com

DEADLINE ALERT for QMCO, TROX, SVRA, FLYE: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions

30 Oct 2025, 17:46 PM
globenewswire.com

LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Savara Inc.

29 Oct 2025, 01:39 AM
globenewswire.com

SVRA DEADLINE ALERT: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

28 Oct 2025, 02:10 AM
globenewswire.com

Deadline Alert: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

27 Oct 2025, 16:00 PM
globenewswire.com

SVRA SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

26 Oct 2025, 13:31 PM
globenewswire.com

SVRA IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action – SVRA

25 Oct 2025, 00:55 AM
globenewswire.com

ROSEN, A LONGSTANDING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– SVRA

21 Oct 2025, 23:47 PM
globenewswire.com

SAVARA CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges Savara, Inc. Investors to Contact the Firm Before November 7th Deadline

18 Oct 2025, 16:39 PM
globenewswire.com

SVRA Lead Plaintiff Deadline (11/7/25) Reminder: Savara Inc. Investors Should Contact Robbins LLP for Information About the Class Action Lawsuit

17 Oct 2025, 21:52 PM
globenewswire.com

Savara Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights – SVRA

16 Oct 2025, 21:00 PM
globenewswire.com

SVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

16 Oct 2025, 17:00 PM
globenewswire.com

SVRA DEADLINE ALERT: Savara Inc. Investors Encouraged to Contact Kirby McInerney LLP Before Important Deadline in Lawsuit

15 Oct 2025, 23:00 PM
globenewswire.com

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SVRA

15 Oct 2025, 21:00 PM
globenewswire.com

Deadline Alert: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

14 Oct 2025, 18:57 PM
globenewswire.com

Class Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors – Contact The Gross Law Firm

13 Oct 2025, 21:00 PM
globenewswire.com

SVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Savara

12 Oct 2025, 13:44 PM
Market Cap
$1,103,320,281
Enterprise Value
$1,091,629,281
P/E
P/B
7.68
P/S
EV / EBITDA
-7.6
EV / Sales
EPS
-0.68
Dividend Yield
0%
P/FCF
P/CF
Free Cash Flow
-$110,660,000
ROE
-96.97%
ROA
-72.5%
Debt / Equity
0.21
Current Ratio
10.13
Quick Ratio
10.13
Cash
2.38
Avg Volume
$1,552,685
Fundamentals Snapshot Price
5.37

Financial statements are not available for this listing.

KindFilingDateLink
edgar index10-Q — Savara IncView Filing
edgar indexS-8 — Savara IncView Filing
edgar index4 — Savara IncView Filing
form 4Form 4 — Lutz Robert MatthewView Filing
form 4Form 4 — Lutz Robert MatthewView Filing
edgar index4 — Savara IncView Filing
edgar index144 — Savara IncView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
edgar index8-K — Savara IncView Filing
eight k text8-K — 8-KView Filing
edgar index10-Q — Savara IncView Filing
edgar indexDEF 14A — Savara IncView Filing
edgar indexDEFA14A — Savara IncView Filing
edgar indexARS — Savara IncView Filing
edgar indexPRE 14A — Savara IncView Filing
edgar index4 — Savara IncView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
form 4Form 4 — Lowrance David LView Filing
edgar index10-K — Savara IncView Filing
edgar index8-K — Savara IncView Filing
eight k text8-K — 8-KView Filing
ten k section10-K — businessView Filing
ten k section10-K — mdaView Filing
ten k section10-K — risk_factorsView Filing
edgar indexSCHEDULE 13G/A — Savara IncView Filing
edgar index4 — Savara IncView Filing
edgar indexSCHEDULE 13G/A — Savara IncView Filing
form 4Form 4 — McCracken Joseph SView Filing
form 4Form 4 — McCracken Joseph SView Filing
edgar indexSCHEDULE 13G/A — Savara IncView Filing
edgar indexSCHEDULE 13G/A — Savara IncView Filing
edgar indexSCHEDULE 13G/A — Savara IncView Filing
edgar index8-K — Savara IncView Filing
eight k text8-K — 8-KView Filing
edgar indexSCHEDULE 13G — Savara IncView Filing
edgar index8-K — Savara IncView Filing
eight k text8-K — 8-KView Filing
edgar index4 — Savara IncView Filing
form 4Form 4 — RAMSAY DAVID AView Filing
edgar index144 — Savara IncView Filing
edgar index4 — Savara IncView Filing